

19 GENNAIO 2023

UNRAVELING THE SAFETY ASPECTS OF
JAK INHIBITORS
FROM A CLINICAL AND
BIOLOGICAL POINT OF VIEW

RATIONALE

The new pharmacological class of JAK inhibitors has already consolidated an important clinical efficacy for patients with rheumatoid arthritis, both when JAKi are used early, i.e., as the first line after the failure of csDMARDs, and in patients failing multiple lines of bDMARDs. Along with efficacy, however, some aspects related to possible safety issues peculiar to this class of drugs emerged. Surely, the growing experience derived from the use of drugs and real-life data will lead to further definition of any problems and better support the clinician decisions about the better therapeutic strategy combining efficacy and safety for each RA patient.

Tackling and deepening the problem from a clinical and biological point of view and in a multidisciplinary way, can help us to better address therapeutic decisions in clinical practice.

Based on these considerations, the aim of this project is to address the main concerns associated with the use of JAK inhibitors, in particular cardiovascular, thrombotic and infectious, from a clinical and biological point of view and in an integrated way with the experts in managing these clinical aspects, to have the most updated skills and knowledge in JAKi management.

SCIENTIFIC DIRECTORS

STEFANO ALIVERNINI - ROMA

ELISA GREMESE - ROMA

FACULTY

FABIO CACCIAPAGLIA - BARI

ANTONELLA CINGOLANI - ROMA

VALERIO DE STEFANO - ROMA

MARCELLO GOVONI - FERRARA

SIMONE PERNIOLA - ROMA

LUCA QUARTUCCIO - UDINE

FRANCESCA ROMANA SPINELLI - ROMA

VINCENZO VENERITO - BARI

PROGRAMME

- 15.00-15.15 Introduction and objectives - *Elisa Gremese, Stefano Alivernini*
- 15.15-15.30 Cardiovascular burden and JAK inhibition in RA - *Francesca Romana Spinelli*
- 15.30-15.45 Biological basis of cardiovascular burden in RA - *Stefano Alivernini*
- 15.45-16.00 Cardiovascular burden: impact of lipid asset - *Fabio Cacciapaglia*
- 16.00-16.10 **Discussion**
- 16.10-16.25 Haematological issues: focus on thrombosis and hematopoiesis in RA and with JAKi
Simone Perniola
- 16.25-16.45 Biological mechanisms of thrombosis and hematopoiesis in RA and with JAKi
Valerio De Stefano, Marcello Govoni
- 16.45-16.55 **Discussion**
- 16.55-17.10 Infectious risk in RA: focus on Herpes zoster - *Vincenzo Venerito*
- 17.10-17.25 Vaccinations in RA: how and when - *Antonella Cingolani*
- 17.25-17.40 JAK inhibition interference on physiopatological mechanisms of immune response
Luca Quartuccio
- 17.40-17.50 **Discussion**
- 17.50-18.05 Shared real-life experience on safety issues - *Elisa Gremese*
- 18.05-18.15 **Discussion**
- 18.15 Final remarks and conclusion

CME & REGISTRATION

The course has been accredited by the Provider Prex (Rif. ECM: 75-369051-1) with educational objective n. 3 and it has been assigned 4,5 credits. The course is reserved to physicians, specialized in: rheumatology, internal medicine, allergology and clinical immunology. To obtain CME credits is necessary to attend the whole course, pass the evaluation test and the evaluation form online. The course is sponsored with the unconditional support by Abbvie.

You may submit your registration on:

<https://www.prex.it/eventi/jaki-safety>



Provider ECM e Segreteria Scientifico-Organizzativa
Via A. Fava, 25 - 20125 Milano - Tel. 02/67972201 - Fax 02/67972300
E-mail: segreteria@prex.it - Website: www.prex.it